Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B P Roques

Showing results (441-450 of 558) with videos related to

Pageof 56
Sort By:
The Biochemical Journal|May 1, 1993
Characterization of neutral endopeptidase 24.11 in dog glomeruliC Landry, P Santagata, W Bawab, et al.
Journal of Medicinal Chemistry|January 8, 1993
CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivativesP J Corringer, J H Weng, B Ducos, et al.
Journal of Medicinal Chemistry|April 3, 1992
Potent and systemically active aminopeptidase N inhibitors designed from active-site investigationM C Fournié-Zaluski, P Coric, S Turcaud, et al.
Biochemical and Biophysical Research Communications|November 14, 1979
Inhibitory potency of various peptides on enkephalinase activity from mouse striatumM C Fournie-Zaluski, R Perdrisot, G Gacel, et al.
The Journal of Biological Chemistry|March 15, 1988
Expression of neutral endopeptidase (enkephalinase) in heterologous COS-1 cells. Characterization of the recombinant enzyme and evidence for a glutamic acid residue at the active siteA Devault, C Nault, M Zollinger, et al.
NIDA Research Monograph|January 1, 1986
[3H]DSTBULET, a new linear hexapeptide with both an improved selectivity and a high affinity for delta-opioid receptorsP Delay-Goyet, C Seguin, V Daugé, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1992
Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and ratsF Noble, J M Soleilhac, E Soroca-Lucas, et al.
Annals of the New York Academy of Sciences|March 23, 1994
CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetrationC Durieux, M Derrien, R Maldonado, et al.
Brain Research|July 17, 1999
The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonistS Le Guen, P Honoré, G Catheline, et al.
Biochemical and Biophysical Research Communications|June 30, 2000
Inhibition of alanyl-aminopeptidase suppresses the activation-dependent induction of glycogen synthase kinase-3beta (GSK-3beta) in human T cellsU Lendeckel, B Scholz, M Arndt, et al.
Pageof 56

Showing results (441-450 of 558) with videos related to

Sort By:
Pageof 56
The Biochemical Journal|May 1, 1993
Characterization of neutral endopeptidase 24.11 in dog glomeruliC Landry, P Santagata, W Bawab, et al.
Journal of Medicinal Chemistry|January 8, 1993
CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivativesP J Corringer, J H Weng, B Ducos, et al.
Journal of Medicinal Chemistry|April 3, 1992
Potent and systemically active aminopeptidase N inhibitors designed from active-site investigationM C Fournié-Zaluski, P Coric, S Turcaud, et al.
Biochemical and Biophysical Research Communications|November 14, 1979
Inhibitory potency of various peptides on enkephalinase activity from mouse striatumM C Fournie-Zaluski, R Perdrisot, G Gacel, et al.
The Journal of Biological Chemistry|March 15, 1988
Expression of neutral endopeptidase (enkephalinase) in heterologous COS-1 cells. Characterization of the recombinant enzyme and evidence for a glutamic acid residue at the active siteA Devault, C Nault, M Zollinger, et al.
NIDA Research Monograph|January 1, 1986
[3H]DSTBULET, a new linear hexapeptide with both an improved selectivity and a high affinity for delta-opioid receptorsP Delay-Goyet, C Seguin, V Daugé, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1992
Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and ratsF Noble, J M Soleilhac, E Soroca-Lucas, et al.
Annals of the New York Academy of Sciences|March 23, 1994
CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetrationC Durieux, M Derrien, R Maldonado, et al.
Brain Research|July 17, 1999
The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonistS Le Guen, P Honoré, G Catheline, et al.
Biochemical and Biophysical Research Communications|June 30, 2000
Inhibition of alanyl-aminopeptidase suppresses the activation-dependent induction of glycogen synthase kinase-3beta (GSK-3beta) in human T cellsU Lendeckel, B Scholz, M Arndt, et al.
Pageof 56